MA31169B1 - Preparation solide comprenant de l'alogliptine et de la pioglitazone - Google Patents

Preparation solide comprenant de l'alogliptine et de la pioglitazone

Info

Publication number
MA31169B1
MA31169B1 MA32148A MA32148A MA31169B1 MA 31169 B1 MA31169 B1 MA 31169B1 MA 32148 A MA32148 A MA 32148A MA 32148 A MA32148 A MA 32148A MA 31169 B1 MA31169 B1 MA 31169B1
Authority
MA
Morocco
Prior art keywords
pioglitazone
solid preparation
alogliptin
sugar
excipient
Prior art date
Application number
MA32148A
Other languages
Arabic (ar)
English (en)
Inventor
Junya Nomura
Kenji Nakamura
Kenichiro Kiyoshima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31169(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31169B1 publication Critical patent/MA31169B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une préparation solide contenant un composé (i), dont la définition est donnée dans la description, et de la pioglitazone, qui est utile comme médicament thérapeutique pour le diabète et similaires et présente des propriétés supérieures de dissolution, de stabilité chimique et de stabilité de dissolution. L'invention porte également sur une préparation solide contenant les première et seconde parties suivantes : (1) la première partie contenant le composé (i) ou un sel de celui-ci et, comme premier excipient, du sucre ou un alcool de sucre ; et (2) une seconde partie contenant de la pioglitazone ou un sel de celle-ci et, comme second excipient, du sucre ou un alcool de sucre.
MA32148A 2007-02-01 2009-08-06 Preparation solide comprenant de l'alogliptine et de la pioglitazone MA31169B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
PCT/JP2008/051900 WO2008093882A1 (fr) 2007-02-01 2008-01-30 Préparation solide comprenant de l'alogliptine et de la pioglitazone

Publications (1)

Publication Number Publication Date
MA31169B1 true MA31169B1 (fr) 2010-02-01

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32148A MA31169B1 (fr) 2007-02-01 2009-08-06 Preparation solide comprenant de l'alogliptine et de la pioglitazone

Country Status (38)

Country Link
US (1) US8637079B2 (fr)
EP (1) EP2107905B1 (fr)
JP (1) JP5284968B2 (fr)
KR (1) KR101486091B1 (fr)
CN (1) CN101646420B (fr)
AR (1) AR065097A1 (fr)
AT (1) ATE488227T1 (fr)
AU (1) AU2008211981B2 (fr)
BR (1) BRPI0807453B8 (fr)
CA (1) CA2677201C (fr)
CL (1) CL2008000279A1 (fr)
CR (1) CR10992A (fr)
CY (1) CY1111264T1 (fr)
DE (1) DE602008003522D1 (fr)
DK (1) DK2107905T3 (fr)
DO (1) DOP2009000195A (fr)
EA (1) EA015180B1 (fr)
EC (1) ECSP099608A (fr)
ES (1) ES2354397T3 (fr)
GE (1) GEP20125410B (fr)
HR (1) HRP20110094T8 (fr)
IL (1) IL200108A (fr)
JO (1) JO2650B1 (fr)
MA (1) MA31169B1 (fr)
ME (1) ME01239B (fr)
MX (1) MX2009008100A (fr)
MY (1) MY147596A (fr)
NZ (1) NZ579008A (fr)
PE (1) PE20081663A1 (fr)
PL (1) PL2107905T3 (fr)
PT (1) PT2107905E (fr)
RS (1) RS51592B (fr)
SI (1) SI2107905T1 (fr)
TN (1) TN2009000317A1 (fr)
TW (2) TW201350143A (fr)
UA (1) UA95828C2 (fr)
WO (1) WO2008093882A1 (fr)
ZA (1) ZA200905621B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (fr) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Formes de sel d'un composé organique
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
WO2010092163A2 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Médicaments antidiabétiques
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
EP2566464A1 (fr) * 2010-05-05 2013-03-13 Boehringer Ingelheim International GmbH Formulations pharmaceutiques comprenant de la pioglitazone et de la linagliptine
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP3517539B1 (fr) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Dérivé de quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement du diabète de type i et ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
US10548848B2 (en) * 2015-06-17 2020-02-04 Hexal Ag Alogliptin formulation
RU2697836C2 (ru) * 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK0559702T3 (da) 1990-11-27 1995-05-15 Byk Gulden Lomberg Chem Fab Urapidil-slow-release-præparat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) * 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
IN192749B (fr) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004067001A1 (fr) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Procede pour realiser une preparation enrobee
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
TWI339586B (en) * 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
JP4361461B2 (ja) 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
JP5122144B2 (ja) 2004-01-20 2013-01-16 ノバルティス アーゲー 直接圧縮製剤および方法
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
EP1807066A1 (fr) 2004-10-25 2007-07-18 Novartis AG Combinaison d'inhibiteur de la dpp-iv, d'antidiabetique ppar et de metformine
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007072992A2 (fr) 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Preparation solide
KR20080081354A (ko) * 2005-12-28 2008-09-09 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제

Also Published As

Publication number Publication date
HRP20110094T8 (en) 2011-07-31
ZA200905621B (en) 2010-10-27
JP2010517937A (ja) 2010-05-27
CA2677201A1 (fr) 2008-08-07
IL200108A0 (en) 2010-04-15
AU2008211981B2 (en) 2012-09-20
ATE488227T1 (de) 2010-12-15
PT2107905E (pt) 2010-12-17
HK1138188A1 (en) 2010-08-20
CR10992A (es) 2009-09-16
SI2107905T1 (sl) 2011-03-31
EP2107905B1 (fr) 2010-11-17
DK2107905T3 (da) 2011-01-31
AU2008211981A1 (en) 2008-08-07
HRP20110094T1 (hr) 2011-03-31
US20100092551A1 (en) 2010-04-15
JP5284968B2 (ja) 2013-09-11
CN101646420A (zh) 2010-02-10
EP2107905A1 (fr) 2009-10-14
BRPI0807453A2 (pt) 2014-05-20
PE20081663A1 (es) 2008-12-25
TN2009000317A1 (en) 2010-12-31
TW200836775A (en) 2008-09-16
BRPI0807453B8 (pt) 2021-05-25
AR065097A1 (es) 2009-05-13
IL200108A (en) 2012-02-29
CY1111264T1 (el) 2015-08-05
TW201350143A (zh) 2013-12-16
DE602008003522D1 (de) 2010-12-30
KR101486091B1 (ko) 2015-01-23
US8637079B2 (en) 2014-01-28
CA2677201C (fr) 2015-11-17
MX2009008100A (es) 2009-08-07
NZ579008A (en) 2012-02-24
EA200970726A1 (ru) 2010-02-26
ES2354397T3 (es) 2011-03-14
UA95828C2 (ru) 2011-09-12
ME01239B (me) 2013-06-20
ECSP099608A (es) 2009-09-29
MY147596A (en) 2012-12-31
WO2008093882A1 (fr) 2008-08-07
PL2107905T3 (pl) 2011-04-29
EA015180B1 (ru) 2011-06-30
RS51592B (sr) 2011-08-31
JO2650B1 (en) 2012-06-17
DOP2009000195A (es) 2009-08-31
CL2008000279A1 (es) 2008-08-18
GEP20125410B (en) 2012-02-27
TWI453041B (zh) 2014-09-21
KR20090109115A (ko) 2009-10-19
BRPI0807453B1 (pt) 2021-01-05
CN101646420B (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
MY147596A (en) Solid preparation comprising alogliptin and pioglitazone
MA30890B1 (fr) Compose indole
Suzuki et al. Structure, activation, and biology of calpain
MA27058A1 (fr) Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant
BR0007820A (pt) Formulações agonistas de exendina e métodos deadministração das mesmas
MA31592B1 (fr) Preparation solide comprenant l'alogliptine et le chlorhydrate de metformine
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA32027B1 (fr) Preparation de capsules
WO2004112701A3 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA32171B1 (fr) Compose heterocyclique
MA29791B1 (fr) Composes therapeutiques.
WO2004064778A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
WO2004103276A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
MA28673B1 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
Azam et al. Parasitic diarrheal disease: drug development and targets
Thiele et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates
HUP9802795A2 (hu) Elhízás kezelésére alkalmas, béta-adrenerg ágenst és étvágycsökkentő hatású vegyületet tartalmazó gyógyászati készítmények
US12605352B2 (en) Compositions and methods for inhibiting blood cancer cell growth
TNSN00139A1 (fr) Acides phenoxyacetiques substitues
Boesecke et al. Toxicity of HIV protease inhibitors: clinical considerations
Nguyen et al. Response: antiapoptotic function of Toso (Faim3) in death receptor signaling
Hou et al. LJNK, an indoline-2, 3-dione-based aminopeptidase N inhibitor with promising antitumor potency
Worz et al. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins